Tech Company Financing Transactions
BrainChild Bio Funding Round
Private investors and WRF Capital participated in a $116 million Series A venture round for BrainChild Bio. The financing round closed on 9/8/2026.
Transaction Overview
Company Name
Announced On
9/8/2026
Transaction Type
Venture Equity
Amount
$116,000,000
Round
Series A
Investors
Proceeds Purpose
The company intends to use the funds to support the ILLUMINATE Phase 2 study evaluating BCB-276 for the treatment of diffuse intrinsic pontine glioma (DIPG) and to support the continued development of BCB-214 for glioblastoma.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
1150 Eastlake Ave 900
Seattle, WA 98109
USA
Seattle, WA 98109
USA
Phone
Undisclosed
Website
Email Address
Overview
BrainChild Bio is a clinical-stage biotechnology company leading the field in the development of CAR T cell therapies for tumors in the central nervous system (CNS). We are kids-first, prioritizing pediatric brain tumors, with a pipeline that extends our technology platform to adult indications, including glioblastoma and brain metastases.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chairman
Nicholas Vitanza
Chief Executive Officer
Steven Brugger
Chief Scientific Officer
Michael Jensen
VP - Bus. Development
Kathi Shah
VP - Human Resources
Jonathan Collins
VP - Operations
Cori Abikoff
VP - Product Management
Rich Getto
VP - R & D
Joshua Gustafson
Browse more venture capital transactions:
Prev: 9/8/2026: Stoke Space Technologies venture capital transaction
Next: 9/8/2026: i2Cool venture capital transaction
Share this article
About Our VC Transactions Data
We record every notable VC transaction. VC investment data records reported here are sourced from a variety of public sources. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs